Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-10-27
1997-03-04
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514473, A61K 3134
Patent
active
056079672
ABSTRACT:
Use of the novel receptor NER TOFA (5-(tetradecyloxy)-2-furan-carboxylic acid) to treat Alzheimer's disease.
REFERENCES:
patent: 4981784 (1991-01-01), Evans et al.
Arbeeny, "Inhibition of fatty acid synthesis decreases renal low density lipoprotein secretion in the hamster", J. Lipid Res. 33: 843-851 (1992).
Ribeneau-Gyon and Gilles, FEBS Lett. 62: 309-312 (1976).
Halvorson and McCune, "Inhibition of fatty acid synthesis in isolated adipocytes by 5-(tetradecyloxy)-2-furoric acid", Lipids 19(11): 851-856 (1984).
Otto et al., "Reciprocal effects of 5-(tetradecyloxy)-2-fuoric acid on fatty acid oxidation", Arch. Biochem. Biophys. 242(1): 23-31, (1985).
Parker et al., "5-(tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids", J. Med. Chem. 20: 781-791 (1977).
Davis et al., "Transcriptional activation by Nur77, a growth factor inducible member of the steroid hormone receptor superfamily" Mol. Endocriniol. 5(6): 854-859, 1991.
Olson, "Reparative strategies in brain-treatment strategies based on trophic factors and cell transfer techniques", Acta Neurochirurgica 58: 3-7, 1993.
Seiger et al., "Intercranial infusion of purified nerve growth factor to an alzheimer patient" Behaviorial Brain Research 57:255-261, 1993.
Power, et al., "Dopamine activation of an orphan of the steroid receptor superfamily", Science 254, pp. 1546-1548, 1991.
Power et al., "New Insights into activation of the steroid hormone receptor superfamily", Trends Pharmacol. Sci. 13(8): 318-323, 1992.
Power et al., "Dopaminergic and igand-independent activation of steroid hormone receptors", Science 254; 1636-1639, 1991.
Lomax and Daniel, "Cocaine and body temperature in the rat: effect of dopamine D1 antagonists", Proc. west Pharmacol. Soc. 34:5-9, 1991.
Witkin et al. "Interaction of haloperidol and SCH23390 with cocaine and dopamine receptor subtype-selective agonists on schedule-controlled behavior of squirrel monkeys", Psychopharmacology Berl. 104(4):452-431, 1991.
Virno et al., "Dopamine, dopaminergic drugs and ocular hypertension", Int. Ophthalmol 16(4-5) 349-353, 1992.
Boyson and Alexander, "Net Production of cerebrospinal fluid is decreased by SCH22390", Ann. Neurol. 27(6): 631-635, 1990.
Lee and Kerlavage, "Molecular biology of G-protein-coupled receptors", Drug News Perspec. 6(7): 488-497, 1993.
Stryer and Bourne, "G proteins, a family of signal transducers", Ann. Rev. Cell. Biol. 2: 391-419, 1986.
Chao et al., "Gene Transfer and Molecular Cloning of the Human NGF Receptor" Science 232: 518-521, 1986.
Levi-Montalcini and Calissano, "The Nerve-Growth Factor" Sci. Amer. 240(6): 68-77. 1979.
Gilman, "G Proteins: Transducers of Receptor-Generated Signals" Ann. Rev. Bichem. 56: 615-49, 1987.
McGurk et al. "Dopaminergic Drugs Reverse the Impairment of Radiol-Arm Maze Performance Caused by Lesions Involving the Cholinergic Medial Pathway", Neuroscience vol. 50, No. 1 pp. 129-135 (1992).
Friedman Eitan
Holloway M. Katharine
Rodan Gideon A.
Schmidt Azriel
Vogel Robert L.
Criares Theodore J.
Fitch Catherine D.
Merck & Co. , Inc.
Quagliato Carol S.
Winokur Melvin
LandOfFree
Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2146285